Process for production of cinnamide derivative

a technology of cinnamide and derivative, which is applied in the direction of group 5/15 element organic compounds, organic chemistry, drug compositions, etc., can solve the problem that the process of producing such compounds has not been known

Inactive Publication Date: 2009-10-29
EISIA R&D MANAGEMENT CO LTD
View PDF48 Cites 30 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0008]An object of the present invention is to provide a process for producing a cinnamide derivative having an amyloid-β production reducing effect, in particular, (3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one, and a process for producing a synthetic intermediate thereof.

Problems solved by technology

However, compounds having a cyclic amide moiety with a cyclic structure such as a pyrrolidone ring or piperidone ring among cinnamide derivatives typified by the structural formula (I) have not yet been known, and accordingly processes for producing such compounds have not been known.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Process for production of cinnamide derivative
  • Process for production of cinnamide derivative
  • Process for production of cinnamide derivative

Examples

Experimental program
Comparison scheme
Effect test

reference example 1

Synthesis of 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde

[0288]

1) Synthesis of 3-methoxy-4-nitrobenzoic Acid Methyl Ester

[0289]Methyl iodide (463 g) was added dropwise to a mixture of 3-hydroxy-4-nitrobenzoic acid (199 g) and potassium carbonate (450 g) in DMF (1 L) at room temperature. The reaction solution was stirred at room temperature overnight and then methyl iodide (230 g) was added to the reaction solution. The reaction solution was further stirred at room temperature for six hours. The reaction solution was added to ice water and the precipitated solid was collected by filtration. The resulting solid was dried at 50° C. overnight to provide 178 g of the title compound. The property values corresponded to the reported values (CAS #5081-37-8).

2) Synthesis of 4-amino-3-methoxybenzoic Acid Methyl Ester

[0290]10% palladium-carbon (containing 50% water, 15 g) was added to a solution of 3-methoxy-4-nitrobenzoic acid methyl ester (150 g) in methanol (600 mL) and THF (300 mL) ...

example 1

Synthesis of 1-[1-(4-fluorophenyl)ethyl]-3-{hydroxy[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methyl}piperidin-2-one

[0299]

[0300]A mixed solution of toluene (86 mL) and tetrahydrofuran (5.8 mL) containing diisopropylamine (10.1 mL, 71 mol, 1.58 equivalents) was cooled in a dry ice bath in a nitrogen atmosphere. n-Butyllithium (2.67 M solution in cyclohexane, 25.4 mL, 68 mmol, 1.5 equivalents) was added dropwise to the diisopropylamine solution at −20° C. After completion of the dropwise addition, the reaction solution was cooled to −70° C. or less and stirred for 30 minutes. Then, a solution of 1-[1-(4-fluorophenyl)ethyl]piperidin-2-one (10 g, 45.2 mol) in toluene (50 mL) was added dropwise to the reaction mixture over 30 minutes. A solution of 3-methoxy-4-(4-methylimidazol-1-yl)benzaldehyde (9.75 g, 45.1 mmol, 1.0 equivalents) in tetrahydrofuran (120 mL) was added dropwise to the reaction mixture over 30 minutes. After completion of the dropwise addition, the temperature of the cool...

example 2

Synthesis of 3-{chloro-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methyl}-1-(4-fluorobenzyl)piperidin-2-one

[0306]

[0307]A solution of 1-[1-(4-fluorophenyl)ethyl]-3-{hydroxy[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methyl}piperidin-2-one (19.1 g) in dimethoxyethane (70 mL) was added dropwise to a solution of thionyl chloride (4.58 mL, 62.7 mol, 2 equivalents) in dimethoxyethane (70 mL) in a nitrogen atmosphere at 10° C. to 23° C. over 10 minutes. The reaction solution was stirred at 20° C. for two hours and then cooled in an ice water bath and toluene (140 mL) was added to the reaction mixture. Subsequently, a 2 N sodium hydroxide solution (140 mL) was added to the reaction mixture. The reaction solution was transferred to a separating funnel and the aqueous layer was discarded. The organic layer was sequentially washed with 5% saline (66 mL×2) and water (5 mL) and dried over anhydrous magnesium sulfate. The solvent was concentrated under reduced pressure to provide 22.1 g of a crude...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to view more

Abstract

A compound (8) represented by the formula: (8)
wherein R1 represents a 6- to 14-membered aromatic hydrocarbon ring group which may have a substituent; and n represents 0 to 2, can be produced with good efficiency by reacting a compound (3) represented by the formula: (3)
wherein R1 and n are as defined above; and Q represents a single bond or —CH(Y)— where Y represents a hydrogen atom or a C1-6 alkyl group] with 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde in the presence of a base.

Description

TECHNICAL FIELD[0001]The present invention relates to a process for producing a cinnamide derivative not yet described in any document, in particular, (3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one having an amyloid-β production reducing effect or the like and useful as a progression inhibitor or prophylactic for a disease involving amyloid-β such as Alzheimer's disease, and to a synthetic intermediate thereof.BACKGROUND ART[0002]Alzheimer's disease is a disease characterized by degeneration and loss of neurons as well as formation of senile plaques and neurofibrillary degeneration. Currently, Alzheimer's disease is treated only with symptomatic treatment using a symptom improving agent typified by an acetylcholinesterase inhibitor, and a fundamental remedy to inhibit progression of the disease has not yet been developed. It is necessary to develop a method for controlling the cause of the onset of pathology in order to cr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C07F9/59C07D401/10C07D211/76
CPCC07D401/10A61P25/28A61P43/00A61K31/4439C07D233/61C07D211/78
Inventor SHIMOMURA, NAOYUKISATO, NOBUAKIKANEKO, TOSHIHIKOTAKAISHI, MAMORUWAKASUGI, KAZUNORIYOSHIKAWA, SEIJINISHIKAWA, YOSHIHIRONAKAMURA, TAIJUFUKUYAMA, TOHRU
Owner EISIA R&D MANAGEMENT CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap